Fintech PR
Singaporean Travellers Reveal the Airlines with Most Delays and Cancellations in MoneySmart Survey
SINGAPORE, June 29, 2023 /PRNewswire/ –– New research released today by leading personal finance portal MoneySmart has revealed the top airlines for flight delay and cancellation according to Singaporean travellers.
Whilst air travel can be notoriously chaotic, travellers have seen an even greater increase in flight disruptions in recent years. In the past 12 months alone, the number of Singaporeans searching for ‘travel insurance claim’ online has risen by 401%¹.
To understand the issues travellers have experienced with flight disruptions, MoneySmart surveyed over 1,700 Singaporeans who have flown in the past year (May 2022-23) and uncovered the top 12 airlines with the most flight delays and cancellations, according to Sinaporean travellers.
Of those surveyed, Air India topped the list, with almost 4 in 5 (78%) of the airline’s customers reporting a delay, while 71% reported a cancellation.
MoneySmart uncovers the airlines Singaporean travellers say they’ve experienced the most disruptions with and how this affected their travel experiences:
The airlines with the most flight delays, as reported by survey respondents
According to the customer survey, Air India emerged as the top airline with the highest number of delays, as reported by almost 4 in 5 (78%) respondents who had flown with them:
- Air China was second, with 7 in 10 (70%) of respondents reporting a delay with them.
- Cebu Pacific Air closely followed in third place, with 69% of respondents encountering delays while flying with the airline.
- Singapore Airlines, the national carrier, was reported to have caused delays for almost 2 in 5 (38%) of the respondents who flew with them in the past year. However, they ranked ninth among the top 12 airlines in terms of reported delays.
The most common duration of delays reported by survey respondents was 1 to 3 hours, accounting for 40% of respondents. Nearly two-fifths (38%) of travellers reported experiencing delays exceeding 4 hours.
The top 12 airlines with the most delays according to Singaporean travellers:
|
Airline |
% of passengers who experienced a delay |
|
Air India |
78 % |
|
Air China |
70 % |
|
Cebu Pacific Air |
69 % |
|
Bangkok Airways |
62 % |
|
Air Asia |
47 % |
|
China Airlines |
46 % |
|
British Airways |
46 % |
|
All Nippon Airways |
43 % |
|
Singapore Airlines |
38 % |
|
Philippine Airlines |
38 % |
|
Scoot |
37 % |
|
Japan Airlines |
37 % |
The airlines with the most flight cancellations, as reported by survey respondents
Excluding flight cancellations due to COVID-19 travel restrictions, Air India took the top spot again, with 71% of survey respondents who had flown with the airline reporting experiencing a cancellation.
- Cebu Pacific Air followed, with 65% who had flown with the airline reporting a cancellation with them.
- Air China claimed the third spot, with over two-thirds (64%) of respondents reporting cancelled flights.
- The survey reveals that the most common wait time for a replacement flight was 1 to 3 hours (27% of respondents).
The top 12 airlines with the most cancellations according to Singaporean travellers:
|
Airline |
% of passengers who experienced a cancellation |
|
Air India |
71 % |
|
Cebu Pacific Air |
65 % |
|
Air China |
64 % |
|
Bangkok Airways |
62 % |
|
British Airways |
37 % |
|
All Nippon Airways |
35 % |
|
Air Asia |
33 % |
|
China Airlines |
33 % |
|
Philippine Airlines |
32 % |
|
Singapore Airlines |
26 % |
|
Cathay Pacific |
25 % |
|
Japan Airlines |
25 % |
Compensation for disruption
When it comes to compensation for disrupted air travel, the survey findings shed light on the following key insights:
Compensation for delayed flights:
- On average, 42% of respondents who had experienced delays reported not receiving direct compensation from the airline.
- Scoot, the low-cost airline owned by the Singapore Airlines group, compensated only around 23% of the surveyed respondents who experienced delays. This places Scoot as the airline least likely to provide compensation for flight delays, leaving 77% of the affected passengers to bear the financial cost.
Compensation for cancelled flights:
- 32% reported not receiving direct compensation from the airline for cancelled flights.
- However, survey responses indicated that Air India – the airline with the highest rate of both delays and cancellations – was least likely to compensate for flight cancellations, with 43% of passengers receiving some.
The percentages of disrupted Singaporean travellers surveyed who received compensation from the top 12 most delayed and cancelled airlines:
|
Delayed travellers |
Cancelled travellers |
|||
|
Airline |
NET % compensated |
Airline |
NET % compensated |
|
|
Air China |
71 % |
Air China |
74 % |
|
|
Bangkok Airways |
66 % |
Singapore Airlines |
73 % |
|
|
British Airways |
64 % |
Bangkok Airways |
59 % |
|
|
Singapore Airlines |
62 % |
Cathay Pacific |
56 % |
|
|
China Airlines |
57 % |
Philippine Airlines |
56 % |
|
|
All Nippon Airways |
53 % |
China Airlines |
54 % |
|
|
Air India |
48 % |
British Airways |
53 % |
|
|
Japan Airlines |
44 % |
Cebu Pacific Air |
51 % |
|
|
Air Asia |
33 % |
Air Asia |
50 % |
|
|
Philippine Airlines |
30 % |
All Nippon Airways |
50 % |
|
|
Cebu Pacific Air |
27 % |
Japan Airlines |
46 % |
|
|
Scoot |
23 % |
Air India |
43 % |
According to respondents who experienced disruptions, the result of flight delays and cancellations has appeared to have a longer-term impact on travel behaviours:
- 65% now always pre-arrange travel insurance to safeguard against travel disruptions, emphasising the growing recognition of its importance.
- 62% found their experience to be stressful, substantiating the emotional toll such incidents can have on travellers.
- 58% now frequently worry about the possibility of future disruptions, indicating a lingering concern affecting their travel plans.
- 47% expressed extreme disappointment with their airline’s handling of delays or cancellations, suggesting a call to improve customer service and support during such frustrating circumstances.
- 39% admitted that the handling of their disruption has made them not want to fly with the airline again, demonstrating a lasting impact of poor incident management on brand trust and customer loyalty.
Abel Lee, Singapore General Manager at MoneySmart said, “Flight delays and cancellations have an immense impact on one’s travel plans.
“Planning for the perfect holiday could all come to waste if we fail to account for these potential risks.
“Our survey has uncovered very recent negative experiences by modern travellers, and we recognise the critical role travel insurance plays in mitigating these risks.
“Travel insurance offers a peace of mind, ensuring that unforeseen disruptions are met with comprehensive support and financial protection that one may not necessarily receive from airlines.
“We believe that every traveller should enjoy a worry-free travel experience.”
For more information and to view the full findings and methodology of the survey, please visit: https://www.moneysmart.sg/travel-insurance/flight-cancellations-delays-singapore-ms
If you choose to run this story, please link back to: https://www.moneysmart.sg/travel-insurance/flight-cancellations-delays-singapore-ms
Accompanying infographics may be downloaded here.
Survey Methodology
Research conducted on behalf of MoneySmart by Savanta amongst 1,730 Singaporean adults (aged 18+) who had travelled in the past year. The survey was carried out online between 5 – 15 May 2023.
Amongst all respondents surveyed, 58% said they had experienced a flight delay, and 40% said they had experienced a cancellation.
All data is based on the experiences, perceptions, and reports of the Singaporean travellers from the above survey group.
Appendix
¹ Google Trends data pulled on 30/5/23 from this page.
About MoneySmart Group
MoneySmart Group is one of Southeast Asia’s largest personal finance portals, helping millions of people on their journey to achieve their financial goals.
MoneySmart provides a financial comparison and content platform for consumers to make informed product choices across a range of banking, insurance and investment products. We do the hard work of compiling the information and facts to make it easy for you to compare and choose what’s best for you.
Under our Bubblegum brand, we aim to create desirable insurance products and experiences and to become the winning digital insurance brand of the future.
For more information, please visit www.moneysmart.com.
View original content:https://www.prnewswire.co.uk/news-releases/singaporean-travellers-reveal-the-airlines-with-most-delays-and-cancellations-in-moneysmart-survey-301866219.html
STOCKHOLM, April 5, 2024 /PRNewswire/ — EQT AB’s Q1 Announcement 2024 will be published on Thursday 18 April 2024 at approximately 07:30 CEST. EQT will host a conference call at 08:30 CEST to present the report, followed by a Q&A session.
The presentation and a video link for the webcast will be available here from the time of the publication of the Q1 Announcement.
To participate by phone and ask questions during the Q&A, please register here in advance. Upon registration, you will receive your personal dial-in details.
The webcast can be followed live here and a recording will be available afterwards.
Information on EQT AB’s financial reporting
The EQT AB Group has a long-term business model founded on a promise to its fund investors to invest capital, drive value creation and create consistent attractive returns over a 5 to 10-year horizon. The Group’s financial model is primarily affected by the size of its fee-generating assets under management, the performance of the EQT funds and its ability to recruit and retain top talent.
The Group operates in a market driven by long-term trends and thus believes quarterly financial statements are less relevant for investors. However, in order to provide the market with relevant and suitable information about the Group’s development, EQT publishes quarterly announcements with key operating numbers that are relevant for the business performance (taking Nasdaq’s guidance note for preparing interim management statements into consideration). In addition, a half-year report and a year-end report including financial statements and further information relevant for investors is published. Finally, EQT also publishes an annual report including sustainability reporting.
Contact
Olof Svensson, Head of Shareholder Relations, +46 72 989 09 15
EQT Shareholder Relations, [email protected]
Rickard Buch, Head of Corporate Communications, +46 72 989 09 11
EQT Press Office, [email protected], +46 8 506 55 334
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/eqt/r/invitation-to-presentation-of-eqt-ab-s-q1-announcement-2024,c3956826
The following files are available for download:
|
Invitation to presentation of EQT AB’s Q1 Announcement 2024 |
|
|
EQT AB Group |
View original content:https://www.prnewswire.co.uk/news-releases/invitation-to-presentation-of-eqt-abs-q1-announcement-2024-302109147.html
- Kia drives forward transformation into ‘Sustainable Mobility Solutions Provider’
- Roadmap enables Kia to proactively respond to uncertainties in mobility industry landscape, including changes in EV market
- Company to expand EV line-up with more models; enhance HEV line-up to manage fluctuation in EV demand
- Goal to sell 1.6 million EVs annually in 2030, introducing 15 models
- PBV to play a key role in Kia’s growth, targeting 250,000 PBV sales annually by 2030 with PV5 and PV7 models
- Kia to invest KRW 38 trillion by 2028, including KRW 15 trillion for future business
- 2024 business guidance : KRW 101 tln in revenue with KRW 12 tln in operating profit; operating profit margin of 11.9% on sales of 3.2 million units globally
- CEO reaffirms Kia’s commitment to ESG management
SEOUL, South Korea, April 5, 2024 /PRNewswire/ — Kia Corporation (Kia) today shared an update on its future strategies and financial targets at its CEO Investor Day in Seoul, Korea.
Based on its innovative achievements in the years since the announcement of mid-to-long-term business initiatives, Kia is focusing on updating its 2030 strategy announced last year and further strengthening its business strategy in response to uncertainties across the global mobility industry landscape.
During the event, Kia updated its mid-to-long-term business strategy with a focus on electrification, and its PBV business. Kia reiterated its 2030 annual sales target of 4.3 million units, including 1.6 million units of electric vehicles (EVs). The 2030 4.3 million annual sales target is 34.4 percent higher than the brand’s 2024 annual goal of 3.2 million units.
The company also plans to become a leading EV brand by selling a higher percentage of electrified models among its total sales, including hybrid electric vehicles (HEV), plug-in hybrid (PHEV), and battery EVs, projecting electrified model sales of 2.48 million units annually or 58 percent of Kia’s total sales in 2030.
“Following our successful brand relaunch in 2021, Kia is enhancing its global business strategy to further the establishment of an innovative EV line-up and accelerate the company’s transition to a sustainable mobility solutions provider,” said Ho Sung Song, President and CEO of Kia. “By responding effectively to changes in the mobility market and efficiently implementing mid-to-long-term strategies, Kia is strengthening its brand commitment to the wellbeing of customers, communities, the global society, and the environment.”
Photo – https://mma.prnewswire.com/media/2380039/Photo_1__2024_CEO_Investor_Day.jpg
PDF – https://mma.prnewswire.com/media/2380040/Press_Release__2024_Kia_CEO_Investor_Day_240405.pdf
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/kia-presents-roadmap-to-lead-global-electrification-era-through-evs-hevs-and-pbvs-302109142.html
VANCOUVER, BC, April 4, 2024 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the “Company“) is providing this bi-weekly update on the status of the management cease trade order granted on February 29, 2024 (the “MCTO“), by its principal regulator, the Ontario Securities Commission (the “OSC“), under National Policy 12-203 – Management Cease Trade Orders (“NP 12-203“), following the Company’s announcement on February 21, 2024 (the “Default Announcement“), that it was unable to file its audited annual financial statements for the year ended October 31, 2023, its management’s discussion and analysis of financial statements for the year ended October 31, 2023, its annual information form for the year ended October 31, 2023, and related filings (collectively, the “Required Annual Filings“). Under National Instrument 51-102, the Required Annual Filings were required to be made no later than February 28, 2024.
As a result of the delay in filing the Required Annual Filings, the Company was unable to file its interim financial statements for the three months ended January 31, 2024, its management’s discussion and analysis of financial statements for the three months ended January 31, 2024, and related filings (collectively, the “Required Interim Filings“). Under National Instrument 51-102, the Required Interim Filings were required to be made no later than April 1, 2024.
The Company anticipates filing the Required Annual Filings by April 30, 2024. The auditor of the Company requires additional time to complete its audit of the Company, including the Company’s recent acquisition of all intellectual property, immunotherapeutics platform technologies, and clinical stage assets of the former IMV Inc. that closed on February 16, 2024. In addition, the Company anticipates filing the Required Interim Filings immediately after the filing of the Required Annual Filings.
Except as herein disclosed, there are no material changes to the information contained in the Default Announcement. In addition, (i) the Company is satisfying and confirms that it intends to continue to satisfy the provisions of the alternative information guidelines under NP 12-203 and issue bi-weekly default status reports for so long as the delay in filing the Required Annual Filings and/or Required Interim Filings is continuing, each of which will be issued in the form of a press release; (ii) the Company does not have any information at this time regarding any anticipated specified default subsequent to the default in filing the Required Annual Filings and Required Interim Filings; (iii) the Company is not subject to any insolvency proceedings; and (iv) there is no material information concerning the affairs of the Company that has not been generally disclosed.
About BioVaxys Technology Corp.
BioVaxys Technology Corp. (www.biovaxys.com), a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it’s HapTenix© ‘neoantigen’ tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The Company’s clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using it proprietary HapTenix© ‘neoantigen’ tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer. The Company is also capitalizing on its tumor immunology know-how and creation of a unique library of T-lymphocytes & other datasets post-vaccination with its personalized immunotherapeutic vaccines to utilize predictive algorithms and other technologies to identify new targetable tumor antigens. BioVaxys common shares are listed on the CSE under the stock symbol “BIOV” and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF). For more information, visit www.biovaxys.com and connect with us on X and LinkedIn.
ON BEHALF OF THE BOARD
Signed “James Passin“
James Passin, Chief Executive Officer
Phone: +1 646 452 7054
Logo – https://mma.prnewswire.com/media/1430981/BIOVAXYS_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/biovaxys-technology-corp-provides-bi-weekly-mcto-status-update-302108920.html
-
Latest News6 days ago
Al Hassan Ghazi Ibrahim Shaker Co. announces a strong start to FY24, reporting a 12.09% YoY increase in net profit to reach SAR 32.25 million in Q1-FY24
-
Latest News6 days ago
Major Korean pension fund invests in carbon solutions with Stafford Capital Partners
-
Latest News5 days ago
Newgen Recognized in the Gartner® Market Guide for Commercial Banking Cash Management and Trade Finance Solutions 2023 Report
-
Latest News5 days ago
Precisely Showcases Critical Role of Trusted Data in AI at the Gartner® Data & Analytics Summit in London
-
Latest News5 days ago
One United Properties posts a consolidated turnover of 84.3 million euros and a gross profit of 37 million euros in the first three months of 2024
-
Latest News4 days ago
Checkout.com’s 4th annual MENA report finds cash on delivery usage halved, amongst maturing digital economy
-
Latest News6 days ago
XREX Singapore Receives MAS Major Payment Institution Licence
-
Latest News5 days ago
KuCoin Research Report Reveals: $1 Billion in Financing and Rising Stablecoin Issuance Amid Market Fluctuations